A multi-center, double-blind, randomized parallel-group Phase IV study comparing the efficacy and safety of thiocolchicoside ointment versus placebo in patients with chronic mechanical low back pain and an acute muscle spasm

This study aims to evaluate the efficacy and safety of thiocolchicoside (TCC) ointment treatment compared to placebo in patients with chronic mechanical low back pain (LBP) accompanied by acute muscle spasms. A total of 292 adult patients (106 males, 186 females; mean age: 38.5±11.2 years; range, 18...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Turkish journal of physical medicine and rehabilitation 2022-12, Vol.68 (4), p.456-463
Hauptverfasser: Ketenci, Ayşegül, Sindel, Dilşad, Tülay Koca, Tuba, Yavuz Karahan, Ali, Erdal, Akın, Aydın, Elif, Sarıfakioğlu, Banu, Ustaömer, Kübra, Talay Çalış, Havva, Sarıkaya, Selda, Sarı, İlker Fatih, Çelik, Canan, Dilek, Banu, Akalın, Elif, Coşkun Benlidayı, İlke, Güzel, Rengin
Format: Artikel
Sprache:eng ; tur
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study aims to evaluate the efficacy and safety of thiocolchicoside (TCC) ointment treatment compared to placebo in patients with chronic mechanical low back pain (LBP) accompanied by acute muscle spasms. A total of 292 adult patients (106 males, 186 females; mean age: 38.5±11.2 years; range, 18 to 64 years) were randomized to TCC group (n=147) and placebo group (n=145) in 12 centers between March 2020 and March 2021. Eight patients from each group were excluded from the analysis. The primary endpoint was pressure pain threshold (PPT) on Day 3, which was measured using a pressure algometer. Secondary endpoints were PPT on Day 7, patient, and physician Visual Analog Scales-pain (VAS-pain) on Days 3 and 7, and safety. The PPT values on Day 3 was not significantly different between the treatment groups (p=0.701). Similarly, TCC and placebo group had similar VAS-pain scores over trial period (p=0.577 or higher for comparisons). Significantly higher PPT values and lower VAS-pain scores on Days 3 and 7 were observed in both groups (p
ISSN:2587-1250
1302-0234
2587-0823
DOI:10.5606/tftrd.2022.9744